SITE007-0170

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-09-17

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-10-25 (study day 26); relationship: not assessed

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-29 (study day 30); relationship: not assessed

severe serious assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-10 (study day 42); relationship: N; serious criteria: hospitalization

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-08 (study day 132); relationship: not assessed

Data queries

No data queries.